While President Donald Trump’s administration catches much of the spotlight in the fight against high drug prices, state governments are also working to implement their own strategies, according to a MedPage Today report.
Nevada Sen. Yvanna Cansela, a Democrat, said during a briefing that 12 percent of the state’s population is diabetic and 28 percent are prediabetic. By 2030, she said, the number of diabetics is set to double.
“At the same time, the cost of insulin has skyrocketed by anywhere from 300 percent to 1,000 percent … ,” she said during the event in Washington sponsored by the Pew Charitable Trusts. “We have a public health crisis that is leaving people unable to afford the medicines they need — in most cases to survive.”
In an effort to take early action, the state in 2017 pushed through bipartisan legislation that addressed the “entire chain of drug pricing.”
Cansela said the law included a number of transparency measures for drugmakers and pharmacy benefit managers.
” … We went all the way down to the pharmaceutical sales representative,” she said.
Lawmakers in Arkansas have focused more heavily on PBMs.
“Most people don’t realize that when they go to the local pharmacy and receive a prescription, the pharmacy doesn’t set the price — it’s set by the PBM,” Arkansas Republican Sen. Ronald Caldwell told MedPage Today. “So when it comes to competition, it’s very hard for someone to compete when they have no authority in setting that price.”